Back to News and Media

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

Publications

This is some text inside of a div block.

October 19, 2025

Media Contacts

Related announcements

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Iambic to Participate in April Investor Conferences